Lonafarnib
- Generic Name
- Lonafarnib
- Brand Names
- Zokinvy
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31Br2ClN4O2
- CAS Number
- 193275-84-2
- Unique Ingredient Identifier
- IOW153004F
- Background
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, a...
- Indication
Lonafarnib is a farnesyltransferase inhibitor indicated in patients aged 12 months and older with a body surface area of at least 0.39 m to reduce the risk of mortality associated with Hutchinson-Gilford progeria syndrome (HGPS). It is also indicated in this same population for the treatment of processing-deficient progeroid laminopathies that either involve...
- Associated Conditions
- Death, Hutchinson-Gilford Progeria Syndrome, Processing-deficient Progeroid Laminopathies
- Associated Therapies
- -
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00020774
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2012-09-12
- Target Recruit Count
- 23
- Registration Number
- NCT00068757
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇫🇷Institut Curie Hopital, Paris, France
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 34
- Registration Number
- NCT00006351
- Locations
- 🇳🇱
University Medical Center Nijmegen, Nijmegen, Netherlands
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 53
- Registration Number
- NCT00015899
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.